Here at the Janssen Health Policy Centre
our mission is to raise awareness on issues impacting healthcare policy, build
consensus through dialogue, and shape recommendations for future policies

Report-09/11/2015
Investing in the future of health

“Investing in the future of health” is an interactive infographic of the current investment landscape in which pharmaceutical research & development operates. Rising healthcare costs and increasing patient populations challenge the current way healthcare is financed and accessible to patients and how innovation is rewarded.

Download pdf
Report-14/09/2015
Investing in European health R&D │ A pathway to sustained innovation and stronger economies

This new study explores the reasons behind Europe’s rising healthcare costs and the corresponding stagnation in R&D investment despite decades of strong growth.

download
Report-22/12/2014
High value, high uncertainty: Measuring risk in biopharmaceutical research and other industries.

Europe's biopharmaceutical industry faces highest business risks among six key industry sectors, according to a new comparative study.

download
Report-02/10/2014
Investing in European health R&D

European research and development investments in health have stagnated since 2010, and this is the first time after decades of annual increases.

download

Investing in the future of health

“Investing in the future of health” is an interactive infographic of the current investment landscape in which pharmaceutical research & development operates. Rising healthcare costs and increasing patient populations challenge the current way healthcare is financed and accessible to patients and how innovation is rewarded. The interactive below guides you through a research- and fact-based storyline demonstrating that investing in healthcare research may have a promising future. Albeit that certain policy conditions need to be met. Data include individual EU countries as well as EU totals and comparisons with US data.

Activate the interactive tool.

This interactive tool is based on the findings of the following research conducted by Deloitte since 2012:

Investing in European Health R&D / A pathway to sustained innovation and stronger economies -“an update of the 2013 publication” - 2015

High value, high uncertainty: measuring risk in biopharmaceutical research and other industries -2014

Investing in European Health R&D/A pathway to sustained innovation and stronger economies - 2013

 

Investing in European health R&D │ A pathway to sustained innovation and stronger economies

This new study explores the reasons behind Europe’s rising healthcare costs and the corresponding stagnation in R&D investment despite decades of strong growth.

The report highlights a number of important findings:

  • Healthcare expenditure is estimated to rise from 13% - 18% of Europe’s GDP by 2030.
  • European R&D healthcare spend represents little more than half of that in the US.
  • The private sector in Europe accounts for two-thirds of R&D investment, with one-third coming from national or EU public funds.
  • While national public health R&D in the EU has risen significantly in the last decade, the pace of growth has slowed since 2009 and stagnated in 2012. Between 2010 and 2012 of all major European economies only Denmark presented growth (17%).
  • The report argues that increased investment in R&D has a fundamental role to play in improved patient care and economic growth in Europe. Such investments also play a fundamental role in responding to the rise in healthcare spending by potentially reducing the burden on already-strained infrastructure.

Download the report

Download the infographic


Download the infographic (web)
Download the infographic (print)
Download the flipbook
 

High value, high uncertainty: Measuring risk in biopharmaceutical research and other industries.

Investing in the future of health

Europe’s biopharmaceutical industry faces highest business risks among six key industry sectors, according to a new comparative study. Economic and societal value of Europe’s biopharmaceutical sector can only be sustained if risks to innovation are adequately rewarded, the study concludes. The study was conducted by Deloitte and commissioned by Janssen. It compares six industry sectors: the biopharmaceutical industry, commercial aircraft manufacturing, the automotive industry, consumer electronics, food manufacturing and generic
pharmaceuticals.

 





 

Download the report here
Download the infographic (web)
Download the infographic (print)
Download the fact sheet
Download the pocket guide

 

Investing in European health R&D

A pathway to sustained innovation and stronger economies

The report “Investing in European health R&D” shows that European research and development (R&D) investments in health have stagnated since 2010, and this is the first time after decades of annual increases. The report was commissioned by Janssen Pharmaceutica NV and the research was conducted by Deloitte Health Economics group.

Why we commissioned the study on health R&D

Some remarks from the researchers

 

R&D investments key for sustainable healthcare

According to the report, this decline is due to the current economic situation, reinforced by the uncertainty about future market conditions, and increasingly limited reward mechanisms for innovative technologies, amongst others. The findings are worrying in the light of Europe’s increasing disease burden and aging population, as well as the millions of people whose health cannot be improved without new health care approaches.

Healthcare costs in Europe are expected to increase to 12-15% of GDP by 2030. The report concludes that increased health R&D investment is even more important to address in the context of growing healthcare expenditure. For example, new technologies improve the quality of healthcare provision, leading to improved outcomes and increased life expectancy. New technologies also lead to efficiency gains, as their cost tends to decrease over time for both medicines and medical devices. Improved health leads to better productivity among the working population and may even increase the maximum working age. Health R&D investments also have the potential to provide high economic yields, both in terms of return on investment and deploying a highly educated workforce with technical skills.

Download the study

Download the Pocket Guide

Download the Infographic


More about “Investing in European health R&D”

 

.terms ul.links { display:none; }

.terms ul.links { display:none; } .play{ top: 50px; *top: -121px; opacity: 0.77; background-image:url("/sites/all/themes/healthpolicy/images/btn_play.png"); background-repeat: no-repeat; background-position: left top; }

  • Janssen Brand
    Janssen Brand
  • Study on health R&D
    Study on health R&D
  • Launching HPC
    Launching HPC
  • Remarks from researchers
    Remarks from researchers

Report archive